Compare Nucor Corporation (NUE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Nucor (NUE) trades at $272.63, up 0.23% on the day, with a bullish technical outlook supported by moving averages and strong resistance near $280. Recent Q2 2026 earnings beat expectations with EPS of $4.84 versus $4.46, driven by record steel shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections at $36.1B. The stock is near its consensus price target of $279.63, with analyst sentiment leaning bullish (59% buy ratings).

Outlook: Nucor benefits from resilient steel demand and operational efficiency, but faces risks from tariff policies and cyclical industry pressures. The current P/E of 21.76 is reasonable given earnings growth, though net margins have compressed from 2022 peaks. Investors should monitor Q3 2026 results against the $5.72 EPS estimate for continued momentum.

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.